Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BGM Group Ltd. stock logo
BGM
BGM Group
$8.47
+5.7%
$8.50
$6.45
▼
$283.20
$101.63M1.888,318 shs5,164 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$5.80
+11.3%
$6.61
$1.85
▼
$9.28
$78.13M0.16237,233 shs167,009 shs
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$1.74
-9.8%
$2.90
$1.72
▼
$14.91
$24.21M787,104 shs159,681 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$2.45
+14.0%
$2.79
$1.62
▼
$5.05
$93.84M2.111.75 million shs1.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BGM Group Ltd. stock logo
BGM
BGM Group
+4.38%-7.29%-13.83%-8.53%-97.16%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-11.39%-2.98%-27.44%-31.72%+146.92%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-2.03%-11.87%-31.56%-42.56%-81.74%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-1.83%-9.66%-17.31%-37.50%-13.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BGM Group Ltd. stock logo
BGM
BGM Group
$8.47
+5.7%
$8.50
$6.45
▼
$283.20
$101.63M1.888,318 shs5,164 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$5.80
+11.3%
$6.61
$1.85
▼
$9.28
$78.13M0.16237,233 shs167,009 shs
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$1.74
-9.8%
$2.90
$1.72
▼
$14.91
$24.21M787,104 shs159,681 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$2.45
+14.0%
$2.79
$1.62
▼
$5.05
$93.84M2.111.75 million shs1.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BGM Group Ltd. stock logo
BGM
BGM Group
+4.38%-7.29%-13.83%-8.53%-97.16%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-11.39%-2.98%-27.44%-31.72%+146.92%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-2.03%-11.87%-31.56%-42.56%-81.74%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-1.83%-9.66%-17.31%-37.50%-13.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BGM Group Ltd. stock logo
BGM
BGM Group
1.00
SellN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
1.00
SellN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
1.67
Reduce$18.00934.48% Upside
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2.50
Moderate Buy$35.001,328.57% Upside

Current Analyst Ratings Breakdown

Latest IXHL, NRXP, CPIX, and BGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/11/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Boost Price TargetBuy$10.00 ➝ $12.00
11/3/2026
BGM Group Ltd. stock logo
BGM
BGM Group
Reiterated RatingSell (E+)
11/3/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingSell (D-)
10/15/2026
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
Reiterated RatingSell (E+)
10/15/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Initiated CoverageOutperform
10/6/2026
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
DowngradeHold ➝ Strong Sell
9/21/2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
Reiterated RatingSell (D-)
9/14/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$10.00
8/26/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy
8/26/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
DowngradeHold ➝ Strong Sell
8/25/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BGM Group Ltd. stock logo
BGM
BGM Group
$37.92M2.83N/AN/A$121.05 per share0.07
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$44.52M1.95$0.41 per share14.21$4.81 per share1.21
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$90K242.63N/AN/A$5.27 per share0.33
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$1.23M86.95N/AN/A($0.54) per share-4.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BGM Group Ltd. stock logo
BGM
BGM Group
-$19.94MN/AN/AN/AN/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$2.84M$4.49N/AN/AN/A274.38%-19.50%-8.12%N/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-$19.30M-$1.24N/AN/AN/AN/A-20.27%-19.15%N/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$28.62M-$0.55N/AN/AN/A-458.48%N/A-50.74%N/A

Latest IXHL, NRXP, CPIX, and BGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.2125-$0.05+$0.1625-$0.05$1.29 million$1.16 million
11/12/2026Q1 2027
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
-$0.44-$0.15+$0.29-$0.15$10.00 millionN/A
9/26/2026Q4 2026
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
$0.13-$0.14-$0.27-$0.2030$0.20 millionN/A
8/28/2026Q2 2026
BGM Group Ltd. stock logo
BGM
BGM Group
N/A-$0.30N/A-$0.0050N/A$12.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BGM Group Ltd. stock logo
BGM
BGM Group
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BGM Group Ltd. stock logo
BGM
BGM Group
N/A
1.25
0.73
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A
3.05
0.96
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
N/A
67.79
67.79
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.86
0.86

Institutional Ownership

CompanyInstitutional Ownership
BGM Group Ltd. stock logo
BGM
BGM Group
N/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
0.43%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%

Insider Ownership

CompanyInsider Ownership
BGM Group Ltd. stock logo
BGM
BGM Group
58.66%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
42.07%
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
9.10%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BGM Group Ltd. stock logo
BGM
BGM Group
29812.69 million5.25 millionN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
9315.00 million8.68 millionOptionable
Incannex Healthcare Inc. stock logo
IXHL
Incannex Healthcare
1212.55 million11.40 millionOptionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2943.65 million41.51 millionOptionable

Recent News About These Companies

What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
NRX Pharmaceuticals (NRXP) Gets a Buy from BTIG
HC Wainwright Issues Negative Forecast for NRXP Earnings
NRx Pharmaceuticals (NRXP) Set to Post Quarterly Earnings on Friday
HC Wainwright Issues Negative Outlook for NRXP Earnings
NRX Pharmaceuticals (NRXP) Receives a Buy from BTIG

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM Group stock logo

BGM Group NASDAQ:BGM

$8.46 +0.46 (+5.68%)
Closing price 03:58 PM Eastern
Extended Trading
$7.75 -0.72 (-8.45%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$5.80 +0.59 (+11.32%)
Closing price 04:00 PM Eastern
Extended Trading
$6.09 +0.29 (+4.93%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Incannex Healthcare stock logo

Incannex Healthcare NASDAQ:IXHL

$1.74 -0.19 (-9.84%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 +0.04 (+2.59%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$2.45 +0.30 (+13.95%)
Closing price 04:00 PM Eastern
Extended Trading
$2.51 +0.06 (+2.41%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.